ArticleInternational medical case reports journal2022

The Role of Brentuximab Vedotin (BV) as Second-Line Treatment of Refractory Classical Hodgkin Lymphoma (cHL) in the Era of Pandemic COVID-19.

Wulyo Rajabto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.